Skip to product information
1 of 1

DATAR

Pinaka

Pinaka

Log in to see the price
Tested biomarkers
View full details

Theranostic Profiling of Circulating Tumor Cells

https://pinaka360.com/

Patients diagnosed with some types of cancers may be advised additional testing of tumor tissue sample to determine the status of biomarkers including ER, PR, HER2 (ERBB2), EGFR and PDL1. The positive status of these biomarkers forms the basis for selection of targeted anticancer agents which are known to be more effective against cancer.

About Pinaka

Pinaka is an advanced non-invasive blood test that provides therapeutically relevant information via a safe, simple, and quick blood draw. Pinaka evaluates blood samples to detect ‘Circulating Tumor Cells’ (CTCs), which are cancer cells that escape from the tumor and enter the bloodstream. Pinaka enriches these CTCs from the blood sample and confirms their identity via a process called ‘Immunocytochemistry’ (ICC). Pinaka also determines the status of the above biomarkers on CTCs either via ICC or by fluorescent in situ hybridization (FISH).

What

A prescription blood test to identify cancer patients who may potentially benefit from the administration of certain types of anti-cancer treatments.

How

Patients undergo a simple blood draw, from which circulating tumor cells are enriched and evaluated for these biomarkers.

For whom

Patients who have been diagnosed with certain types of cancers, for whom the NCCN guidelines recommend evaluation of ER, PR, HER2, EGFR, or PDL1 status on tumor tissue to determine whether the patient may benefit from administration of respective targeted anti-cancer treatments.

Why

Evaluation of these biomarkers may not be possible on tumor tissue due to sample insufficiency or inability to obtain samples. False negatives may arise due to low tumor content or tumor heterogeneity. Pinaka™ is a safe and viable option to evaluate the status of these biomarkers in cases where a tissue-based biomarker assessment has been inconclusive or is not possible.

Reliable Technology

Pinaka™ evaluates the status of the above biomarkers on CTCs, which are known to be present (and detected ubiquitously) in the indicated cancer types, irrespective of age, gender, disease stage, grade of disease, or treatment status. Since CTCs are essentially tumor cells, their analysis is comparable to analysis of tumor tissues. Our own acclaimed clinical studies (as well as other prior studies) have shown that CTC-based determination of the above biomarkers has high concordance with tumor tissue-based determinations.

Advantages

The technology of Pinaka™ is based on the ubiquity of CTCs and the highly efficient CTC detection process. This technology has a low false negative rate (high ‘sensitivity’) as well as a low false positive rate (high ‘specificity’). These factors translate into a safe blood test for accurate and reliable determination of the status of the above biomarkers.

  • Non-invasive, safe, convenient, and patient-friendly
  • A viable alternative where tumor tissue-based biomarker analysis is unavailable or has been inconclusive
  • No need for hospitalization/visit to an advanced healthcare facility
  • No risks of pain, bleeding, or infection
  • Suitable for use at any stage of the clinical management pathway
  • Suitable for radiologically undetectable tumors
  • Not prone to intra and inter-tumoral heterogeneity

For more information, please visit https://pinaka360.com/technology/


Certifications/accreditations of Datar Cancer Genetics

Certifications of Datar Cancer Genetics